TSE:4565Pharmaceuticals
Nxera Pharma TSE 4565 Q4 EPS Loss Deepens Challenging Growth Optimism
Nxera Pharma (TSE:4565) FY 2025 earnings: revenue steady, losses widen
Nxera Pharma (TSE:4565) has posted its FY 2025 results with Q4 revenue at ¥7,767 million and a basic EPS loss of ¥85.32, alongside trailing twelve month revenue of ¥29,615 million and a net loss of ¥12,530 million. The company has seen quarterly revenue range between ¥6,644 million and ¥8,450 million over FY 2025, while basic EPS moved from a loss of ¥8.45 in Q1 to a loss of ¥85.32 in Q4. These figures may prompt investors...